Edesa Biotech Valor contable por acción
¿Qué es el Valor contable por acción de Edesa Biotech?
El Valor contable por acción de Edesa Biotech, Inc. es 1.77
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en NASDAQ en comparadas con Edesa Biotech
¿Qué hace Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Empresas con valor contable por acción similar a Edesa Biotech
- Sky Solar tiene Valor contable por acción de 1.76
- Patriot National Bancorp Inc tiene Valor contable por acción de 1.76
- INmune Bio tiene Valor contable por acción de 1.77
- Extraction Oil & Gas tiene Valor contable por acción de 1.77
- Logic Instrument S.A tiene Valor contable por acción de 1.77
- LINK Mobility ASA tiene Valor contable por acción de 1.77
- Edesa Biotech tiene Valor contable por acción de 1.77
- Lifestyle International tiene Valor contable por acción de 1.77
- Naked Wines plc tiene Valor contable por acción de 1.77
- Dicerna Pharmaceuticals Inc tiene Valor contable por acción de 1.77
- Vulcan Resources tiene Valor contable por acción de 1.77
- Gold Rush Cariboo tiene Valor contable por acción de 1.77
- Westwater Resources Inc tiene Valor contable por acción de 1.77